Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients

Abstract

Purpose The aim of this study was to compare the effect ranibizumab and aflibercept in the treatment of macular edema secondary to nonischemic central retinal vein occlusion (CRVO) in young adults. Patients and methods This is a prospective double-armed clinical trial that enrolled 40 eyes of 40 young adult patients (aged 0.05). Regarding the central subfield thickness (CST), in the first group, a statistically significant decrease in the CST was reported over time from a baseline value of 557.85±69.7–295.1±55.9 μm at 1 year (P0.05). Conclusion Ranibizumab and aflibercept showed a comparable promising outcome in the management of macular edema secondary to nonischemic CRVO in patients aged less than 50 years. Further multicentric randomized clinical trials are needed to confirm these results.

Keywords

• aflibercept
• intravitreal injection
• nonischemic central retinal vein occlusion
• ranibizumab